Asgard Therapeutics is a private biotech company exploring the application of direct cell reprogramming technologies for cancer immunotherapies. Formed as a spin-off from Lund University, the Company is pioneering a gene therapy approach based on its proprietary TrojanDC technology, designed to set in motion immune responses based on the biologicalproperties of professional antigen-presenting cells.

Biotechnology

Therapeutics

Asgard Therapeutics

Cristiana Pires

Shane Olwill

Jan K. Villadsen

Johanna Olweus

Jonas Jendi

Aurélien Marabelle

João Ribas

Martin Bonde

Joshua Brody

Ignacio Melero

Philipp Müller

Cristina Csimma

Ulrich Lauer

Brian Brown

Aleksei Zeifman

The Research and Development team at Asgard Therapeutics focuses on advancing innovative gene therapy techniques, specifically utilizing TrojanDC technology to enhance cancer immunotherapy. With a diverse skill set that includes expertise in cell reprogramming and preclinical pharmacology, the team collaborates on designing and executing experimental protocols, analyzing data, and translating findings into clinical applications to improve immune responses against cancer.

Research and Development

Asgard Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Offices

Asgard Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Offices

Related companies